Podimetrics v. Bluedrop Medical: Foot-Scanning Patent Suit Dismissed Without Prejudice
Podimetrics, Inc. asserted four patents covering diabetic foot temperature-monitoring technology against Bluedrop Medical’s OneStep and Delta Foot Scanners. The case resolved in 129 days when Podimetrics filed a voluntary dismissal under Rule 41(a)(1)(A)(i), leaving all claims dismissed without prejudice — preserving the right to refile.
Four Foot-Monitoring Patents, One Swift Voluntary Exit
On June 24, 2024, Podimetrics, Inc. filed suit against Bluedrop Medical, Ltd. in the Texas Southern District Court (Case No. 3:24-cv-00188) before Judge Jeffrey V. Brown, asserting infringement of four US patents — US9271672B2, US9259178B2, US9095305B2, and US9326723B2 — all directed to diabetic foot temperature-monitoring systems. The accused products were Bluedrop’s OneStep Foot Scanner and Delta Foot Scanner, which compete with Podimetrics’ SmartMat™ platform.
The case closed on October 31, 2024, just 129 days after filing. On October 30, 2024, Podimetrics filed a notice of voluntary dismissal under Fed. R. Civ. P. 41(a)(1)(A)(i) — a unilateral procedural mechanism available before the defendant files an answer or a motion for summary judgment. The court ordered all claims dismissed without prejudice, meaning Podimetrics can refile the same claims against Bluedrop in the future.
The speed of resolution — and the absence of any defendant law firm on record — suggests the case may have ended before Bluedrop formally appeared, which is the precise window Rule 41(a)(1)(A)(i) permits unilateral withdrawal. Whether this reflects a confidential settlement, a strategic repositioning of Podimetrics’ enforcement approach, or a decision to pursue alternative venues remains unknown from the public record. The without-prejudice designation keeps Podimetrics’ enforcement options fully open.
Filing to Voluntary dismissal in 129 days
129 days — resolved well under the median district court patent case duration of ~2.5 years
Dismissed without prejudice: what the voluntary exit means for both parties
Rule 41(a)(1)(A)(i): plaintiff’s unilateral right to withdraw
Fed. R. Civ. P. 41(a)(1)(A)(i) allows a plaintiff to dismiss its own case without a court order — and without the defendant’s consent — before the defendant serves an answer or a motion for summary judgment. This is a one-time, cost-free exit. The court’s order confirming dismissal without prejudice is consistent with the automatic effect of the rule.
Procedural exit — no merits adjudicatedWithout prejudice: the claims survive for a future action
A dismissal without prejudice means Podimetrics’ infringement claims are not extinguished. The same four patents can be reasserted against Bluedrop — or any other party — in a future lawsuit. This contrasts sharply with a with-prejudice dismissal, which would bar re-litigation. The public record confirms the without-prejudice designation explicitly in the court’s October 30 order.
Claims preserved — refiling permittedBluedrop exits with no adverse ruling — but no certainty
Bluedrop Medical secures a clean exit from this particular action with no finding of infringement and no injunction. However, the without-prejudice dismissal offers no legal shield against future suit. If Bluedrop continues to sell the OneStep or Delta Foot Scanners, it remains exposed to reassertion of the same four Podimetrics patents. The lack of any recorded defendant counsel suggests Bluedrop may not have formally appeared before the dismissal was filed.
No adverse ruling — future risk remainsPatent enforcement clock is still running in diabetic foot monitoring
The voluntary exit before substantive engagement leaves the validity and scope of all four Podimetrics patents untested. Competitors in the diabetic foot temperature-monitoring space — including makers of thermometric foot mats, smart insoles, and remote patient monitoring platforms — cannot draw comfort from this outcome. Podimetrics retains a live enforcement position across a four-patent portfolio covering core technology in this growing medtech segment.
Enforcement posture intactFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Podimetrics, Inc. | Company | Diabetic foot monitoring medtech — holder of US9271672B2 and three related patentsSearch in Eureka ↗ |
| Defendant | Bluedrop Medical, Ltd. | Company | Bluedrop Medical, Ltd. — maker of the OneStep and Delta Foot Scanners for diabetic foot assessmentSearch in Eureka ↗ |
| Plaintiff counsel | Amir H. Alavi | Attorney | Counsel for Podimetrics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Benjamin M Stern | Attorney | Counsel for Podimetrics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Demetrios Anaipakos | Attorney | Counsel for Podimetrics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Micah Miller | Attorney | Counsel for Podimetrics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Alavi & Anaipakos PLLC | Law Firm | Representing Podimetrics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Nutter, McClennen & Fish LLP | Law Firm | Representing Podimetrics, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Jeffrey V Brown | Judge | Texas Southern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order tracks the mechanical operation of Rule 41(a)(1)(A)(i): because Podimetrics filed its notice before Bluedrop served an answer or a summary judgment motion, dismissal was effective as of right. The explicit without-prejudice qualifier in the order is significant — it confirms no forfeiture of claims and leaves Podimetrics free to reassert all four patents. No merits determination, claim construction, or validity finding was made, so the legal landscape between these parties is unchanged from the day before filing.
US9271672B2 — Diabetic Foot Temperature Monitoring Systems
The four asserted patents — US9271672B2, US9259178B2, US9095305B2, and US9326723B2 — originate from US application filings between 2013 and 2015 and cover systems and methods for monitoring plantar foot temperature in diabetic patients. The core technical concept involves detecting temperature asymmetries across the foot surface as early indicators of diabetic foot ulcer risk, typically via a mat or scanning device used in home or clinical settings. This positions the patents squarely in the remote patient monitoring and digital health sectors.
Diabetic foot complications represent a major clinical and commercial burden, driving significant investment in non-invasive monitoring hardware and connected health platforms. A four-patent cluster covering thermometric scanning methods creates a broad perimeter around this product category. Any device that measures plantar temperature differentials and transmits or processes that data for ulcer-risk assessment is plausibly within claim scope — making this portfolio strategically significant for both incumbents and new entrants in the diabetic foot care market.
Should your foot-scanning product be cleared against Podimetrics’ patent family?
Any company developing or commercialising thermometric foot scanning devices, diabetic foot monitoring mats, smart insoles, or remote patient monitoring platforms for diabetic foot care should conduct an FTO assessment against the Podimetrics patent family. The four patents cover a range of system architectures and method claims, and the voluntary dismissal in this case leaves all claims legally intact and enforceable. The SmartMat™ product context confirms these patents are actively commercialised and therefore likely to be enforced.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map product features against claim-level language across all four Podimetrics patents simultaneously, surface related family members, and identify prior art that could inform design-around or invalidity strategies. Running an FTO now — before a second enforcement action is filed — provides the clearest window for strategic decision-making without litigation pressure.
Run a freedom-to-operate analysis on US9271672B2 to assess your product’s exposure
Run FTO in Eureka →Similar Patent Disputes in Diabetic Foot Monitoring & Remote Patient Monitoring
Cases involving thermometric foot scanning and remote diabetic patient monitoring patents in US district courts, including related Rule 41 voluntary dismissals in medtech.
What this case signals for the diabetic foot monitoring IP landscape
A swift voluntary exit preserving all claims is rarely the end of the story in medtech patent enforcement.
Without-prejudice dismissals in medtech often precede re-filed or restructured claims
When a plaintiff files and then voluntarily withdraws under Rule 41(a)(1)(A)(i) before the defendant appears, it typically signals a strategic recalibration — not surrender. Podimetrics retains all four patents and the right to refile. Competitors should treat this as a temporary pause, not a cleared landscape.
No defendant counsel on record narrows the window for early prior-art arguments
The absence of a defendant law firm in the case record suggests Bluedrop did not formally engage before dismissal. This means no invalidity arguments, claim construction disputes, or IPR petitions were triggered. The four asserted patents remain unchallenged and in full force.
Podimetrics v Bluedrop — key questions answered
The case was dismissed without prejudice. On October 30, 2024, Podimetrics filed a notice of voluntary dismissal under Rule 41(a)(1)(A)(i), and the court ordered all claims dismissed without prejudice to refiling. Podimetrics retains the right to reassert the same four patents against Bluedrop in a future action.
Podimetrics asserted four US patents: US9271672B2, US9259178B2, US9095305B2, and US9326723B2. All relate to diabetic foot temperature-monitoring systems and methods, filed from US application numbers between 2013 and 2015. The accused products were Bluedrop’s OneStep Foot Scanner and Delta Foot Scanner.
Rule 41(a)(1)(A)(i) allows a plaintiff to dismiss its lawsuit without a court order or defendant consent, as long as the defendant has not yet filed an answer or motion for summary judgment. The dismissal is without prejudice by default unless the plaintiff specifies otherwise. In patent cases this mechanism is commonly used when parties reach a confidential resolution or when the plaintiff wishes to refile in a different venue or posture.
The public record does not disclose Podimetrics’ reason for dismissal. Possible explanations include a confidential settlement or licensing agreement, a strategic decision to refile in a different jurisdiction, or a reassessment of claim mapping against the accused products. The without-prejudice designation and the absence of any recorded defendant counsel suggest the dismissal occurred very early in the litigation lifecycle.
No. A voluntary dismissal without prejudice has no effect on patent validity. No claim construction, invalidity finding, or merits ruling was issued. All four asserted patents — US9271672B2, US9259178B2, US9095305B2, and US9326723B2 — remain in force and enforceable. Third parties cannot rely on this outcome as any indication that the patents are weak or unchallenged.
PatSnap Eureka searches patents and litigation data to answer instantly.